CHICAGO TRUST Co NA Purchases Shares of 1,125 Insulet Co. (NASDAQ:PODD)

CHICAGO TRUST Co NA bought a new position in Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,125 shares of the medical instruments supplier’s stock, valued at approximately $294,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. QRG Capital Management Inc. purchased a new position in shares of Insulet during the 3rd quarter worth about $297,000. Fisher Asset Management LLC boosted its holdings in shares of Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after buying an additional 3,113 shares in the last quarter. Orion Portfolio Solutions LLC increased its position in Insulet by 86.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after buying an additional 3,623 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of Insulet by 5.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after buying an additional 8,301 shares during the last quarter. Finally, Stifel Financial Corp grew its stake in Insulet by 2.8% during the 3rd quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier’s stock valued at $2,450,000 after purchasing an additional 290 shares during the last quarter.

Insulet Stock Down 1.4 %

PODD stock opened at $267.99 on Tuesday. The stock has a market cap of $18.80 billion, a PE ratio of 45.89, a price-to-earnings-growth ratio of 4.12 and a beta of 1.22. The firm’s 50-day simple moving average is $264.57 and its 200 day simple moving average is $230.93. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.77. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insider Transactions at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on PODD. Citigroup upped their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. BTIG Research upped their target price on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James raised their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Finally, Barclays boosted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $272.81.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.